RyboDyn Achieves a Milestone with Lilly Gateway Labs
In an exciting development, RyboDyn, Inc., a biotechnology innovator, has been selected to join the prestigious Lilly Gateway Labs (LGL) program. This partnership marks a significant step forward in RyboDyn's mission to pioneer immunotherapies that target the dark proteome, a largely unexplored area within cancer treatment.
Access to Cutting-Edge Resources
Joining the LGL provides RyboDyn invaluable access to Eli Lilly and Company’s extensive scientific and business networks. This relationship is expected to be a key driver as RyboDyn advances its leading programs, utilizing the infrastructure and support that LGL offers to early-stage biotechnology firms.
Focus on Dark Proteome Discovery
RyboDyn has made remarkable progress since discovering a cryptic proteome. This previously uncharacterized layer of genetic potential includes proteins linked to cancer that can be targeted by therapies. By employing their proprietary platform, RyboCypher™, RyboDyn has identified a set of therapeutic targets that are critical for cancer treatment strategies.
Collaboration with Leading Institutions
The collaboration with Moffitt Cancer Center underlines the potential of these Dark Targets™, showcasing that many of them are conserved among patients. This finding strengthens RyboDyn's commitment to fostering first-in-class, precision immunotherapies that have the potential to revolutionize cancer treatment.
Vision for Future Programs
Dr. Imad Ajjawi, CEO and Co-founder of RyboDyn, expressed enthusiasm about joining the LGL community. He emphasized the importance of collaborating with like-minded peers who share a passion for translating high-impact scientific discoveries into successful therapeutic advancements.
Part of a Broader Strategy
RyboDyn's residency in Lilly Gateway Labs is part of the Lilly Catalyze360™ model, which is designed to provide innovative biotech startups with comprehensive resources. This initiative facilitates access to world-class laboratories, drug development expertise, and financial support, empowering RyboDyn in its ambitious journey toward bringing new therapies to market.
Accelerating Therapeutic Development
Set within the impressive One Alexandria Square Megacampus in Torrey Pines, California, RyboDyn is now positioned to meaningfully progress its dark proteome research into novel therapeutics. Staying focused on strategic partnerships is key as the company aims to advance its research pipeline toward human clinical trials.
About RyboDyn
Founded in San Diego, CA, RyboDyn, Inc. pioneers innovative solutions in the biotechnology landscape. It is dedicated to the development of groundbreaking immunotherapies targeting the dark genome. Leveraging RyboCypher™, an advanced sequencing and AI-driven platform, RyboDyn works toward identifying and validating previously unknown proteins and disease-specific targets.
With a robust intellectual property portfolio licensed from an esteemed university, RyboDyn is implementing a unique approach that takes innovative targets to actionable assets in therapy development. The company collaborates with top-tier clinical institutions, academic partners, and biopharma organizations to validate its promising drug pipeline, focusing on transformative treatments for cancer and other diseases.
Frequently Asked Questions
What is the main focus of RyboDyn?
RyboDyn focuses on pioneering first-in-class immunotherapies that target the dark proteome in the context of cancer treatment.
What advantages does joining Lilly Gateway Labs provide?
Joining Lilly Gateway Labs provides RyboDyn access to Eli Lilly’s extensive network, resources, and support for furthering their therapeutic programs.
How does RyboDyn discover new therapeutic targets?
RyboDyn utilizes its proprietary platform, RyboCypher™, to uncover cancer-specific therapeutic targets from a previously uncharacterized layer of genetic potential.
Who is leading RyboDyn?
Dr. Imad Ajjawi is the CEO and Co-founder of RyboDyn, guiding the company through its innovative developments in biotechnology.
Where is RyboDyn based?
RyboDyn is headquartered in San Diego, California, where it conducts its research and development activities.
